The two collaborators aim to develop a prophylactic vaccine based on Evaxion’s EDEN-discovered gonorrhea targets.
“We are thrilled about this partnership. It offers a unique opportunity to deliver our EDEN-identified antigens using mRNA and it accelerates clinical validation of the EDEN platform. This partnership has the potential to address a serious unmet global medical need against the pathogen for which no vaccine currently exists,” says Evaxion’s Chief Scientific Officer, Birgitte Rønø.
The expression and biological activity of the antigens in mRNA format
This partnership will explore the expression and biological activity of the antigens in mRNA format. Following the validation phase, the partners will negotiate a subsequent agreement for clinical development and commercialization, with the opportunity to bring in additional partners.
We are excited to announce Evaxion’s second partnership this week.”
“We are excited to announce Evaxion’s second partnership this week. This is a further validation of our strategy to identify the right partners who can bring our novel AI-designed vaccines to the market,” says Evaxion CEO Christian Kanstrup.